Immune Suppression Of Infants Treated With Steroids

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to clarify the degree of immune suppression in infants requiring therapy and to create guidelines for evaluation and prevention of infection in infants on oral steroids for hemangiomas.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical College of Wisconsin
• Treatments: Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Infants < 6 months of age with infantile hemangiomas requiring treatment with oral corticosteroids

• Infant must be enrolled prior to initiation of steroid therapy

Exclusion Criteria:

• Infants > 6 months of age

• Infants already receiving oral corticosteroid treatment prior to the start of this study

• Infants with know immunodeficiencies

• Infants receiving other oral medications for the treatment of hemangiomas